,src,lang,text
0,"











Zydus Cadila receives USFDA warning letter for its Moraiya facility
The company remains committed to patient safety and meeting the expectations of regulatory compliances, the Gujarat-based firm said.
04 Nov 2019, 11:10 by Press Trust of India
Drug firm Zydus Cadila on Monday said it has received a warning letter from the US health regulator for its Moraiya-based formulation facility.
The company said it has already taken multiple steps after the inspection of the facility by the US Food and Drug Administration (USFDA) and would continue to take all necessary steps in future as well to ensure that the health regulator is fully satisfied with its remediation of the above facility.
""We are confident of responding to the USFDA to address the observations within the statutory time permitted in the letter,"" Zydus Cadila said in a regulatory filing.
The warning letter does not affect the existing business of the company in the US and the existing product supplies from the Moraiya facility will continue, it added.
The company remains committed to patient safety and meeting the expectations of regulatory compliances, the Gujarat-based firm said.
Shares of Cadila Healthcare, the listed entity of the company, on Monday closed nearly 5.6 per cent down on the BSE.


",en,"











Zydus Cadila receives USFDA warning letter for its Moraiya facility
The company remains committed to patient safety and meeting the expectations of regulatory compliances, the Gujarat-based firm said.
04 Nov 2019, 11:10 by Press Trust of India
Drug firm Zydus Cadila on Monday said it has received a warning letter from the US health regulator for its Moraiya-based formulation facility.
The company said it has already taken multiple steps after the inspection of the facility by the US Food and Drug Administration (USFDA) and would continue to take all necessary steps in future as well to ensure that the health regulator is fully satisfied with its remediation of the above facility.
""We are confident of responding to the USFDA to address the observations within the statutory time permitted in the letter,"" Zydus Cadila said in a regulatory filing.
The warning letter does not affect the existing business of the company in the US and the existing product supplies from the Moraiya facility will continue, it added.
The company remains committed to patient safety and meeting the expectations of regulatory compliances, the Gujarat-based firm said.
Shares of Cadila Healthcare, the listed entity of the company, on Monday closed nearly 5.6 per cent down on the BSE.


"
